Characteristics | Total (n = 2,335) | Quartiles of TyG-BMI | P value | ||||
---|---|---|---|---|---|---|---|
Q1 (n = 584) < 165.5 | Q2 (n = 584) 165.5-<183.7 | Q3 (n = 584) 183.7-<209.2 | Q4 (n = 583) > 209.2 | ||||
Age (years) | 46.1 ± 14.8 | 40.4 ± 15.1 | 45.2 ± 15.1 | 46.7 ± 13.8 | 50.2 ± 13.3 | < 0.001* | |
Male sex (n, %) | 1382 (59.2) | 296 (50.7) | 357 (61.1) | 376 (64.4) | 353 (60.5) | < 0.001* | |
Dialysis duration (months) | 46.6 (22.4–78.0) | 48.8 (21.8–89.0) | 46.0 (21.6–76.2) | 47.9 (24.4–75.3) | 43.5 (21.9–70.7) | 0.076 | |
Primary renal diseases | Â | Â | Â | Â | Â | Â | |
Glomerulonephritis (n, %) | 1432 (61.3) | 461 (78.9) | 395 (67.6) | 325 (55.7) | 251 (43.1) | < 0.001* | |
Diabetic nephropathy (n, %) | 480 (20.6) | 33 (5.7) | 78 (13.4) | 143 (24.5) | 226 (38.8) | < 0.001* | |
Renal vascular diseases (n, %) | 179 (7.7) | 23 (3.9) | 43 (7.4) | 51 (8.7) | 62 (10.6) | < 0.001* | |
Others (n, %) | 244 (10.4) | 67 (11.5) | 68 (11.6) | 65 (11.1) | 44 (7.5) | 0.069 | |
BMI (kg/m2) | 21.8 ± 3.2 | 18.4 ± 1.5 | 20.5 ± 1.3 | 22.5 ± 1.4 | 25.6 ± 2.6 | < 0.001* | |
Systolic pressure (mmHg) | 136 ± 20 | 135 ± 19 | 137 ± 20 | 136 ± 20 | 136 ± 21 | 0.617 | |
Diastolic pressure (mmHg) | 85 ± 14 | 87 ± 13 | 86 ± 14 | 84 ± 14 | 83 ± 13 | < 0.001* | |
Urine output (ml) | 1000 (600–1500) | 900 (500–1400) | 1000 (600–1500) | 1000 (700–1600) | 1100 (600–1700) | < 0.001* | |
Comorbidities | Â | Â | Â | Â | Â | Â | |
Diabetes (n, %) | 564 (24.2) | 41 (7.0) | 96 (16.4) | 170 (29.1) | 257 (44.1) | < 0.001* | |
CVD history (n, %) | 782 (33.5) | 136 (23.3) | 181 (31.0) | 213 (36.5) | 252 (43.2) | < 0.001* | |
Hypertension (n, %) | 664 (28.4) | 79 (13.5) | 155 (26.5) | 188 (32.2) | 242 (41.5) | < 0.001* | |
Laboratory parameters | Â | Â | Â | Â | Â | Â | |
Hemoglobin (g/l) | 101 ± 22 | 101 ± 24 | 101 ± 22 | 101 ± 22 | 101 ± 20 | 0.900 | |
Albumin (g/l) | 36.1 ± 5.1 | 36.9 ± 5.3 | 36.7 ± 4.9 | 36.5 ± 5.1 | 36.6 ± 5.1 | 0.593 | |
Triglyceride (mg/dl) | 124 (89–178) | 91 (68–122) | 116 (89–156) | 130 (98–172) | 186 (134–274) | < 0.001* | |
FBG (mg/dl) | 84.6 (75.6–100.8) | 79.2 (70.2–86.4) | 84.6 (75.6–95.4) | 88.2 (77.4–104.4) | 95.4 (82.8–138.6) | < 0.001* | |
TyG index | 8.62 (8.23–9.08) | 8.17 (7.88–8.49) | 8.54 (8.23–8.85) | 8.69 (8.38–9.04) | 9.20 (8.78–9.65) | < 0.001* | |
Total cholesterol (mg/dl) | 193 ± 52 | 185 ± 49 | 192 ± 50 | 196 ± 50 | 202 ± 55 | < 0.001* | |
HDL-C (mg/dl) | 47.5 ± 16.3 | 54.4 ± 18.2 | 49.2 ± 16.5 | 45.7 ± 13.5 | 40.8 ± 13.2 | < 0.001* | |
LDL-C (mg/dl) | 114 ± 39 | 108 ± 35 | 115 ± 37 | 119 ± 39 | 116 ± 42 | < 0.001* | |
Serum creatinine (mg/dl) | 8.74 ± 3.10 | 8.82 ± 3.14 | 8.84 ± 3.20 | 8.64 ± 2.83 | 8.68 ± 3.23 | 0.661 | |
Uric acid (mg/dl) | 7.15 ± 1.63 | 7.03 ± 1.60 | 7.17 ± 1.64 | 7.07 ± 1.62 | 7.32 ± 1.66 | 0.009* | |
Urea nitrogen (mg/dl) | 49.8 ± 29.2 | 50.7 ± 21.0 | 49.2 ± 20.4 | 50.6 ± 20.2 | 48.9 ± 19.2 | 0.240 | |
eGFR (ml/min/1.73 m2) | 6.73 ± 2.84 | 6.75 ± 2.71 | 6.73 ± 2.87 | 6.70 ± 2.65 | 6.73 ± 3.12 | 0.926 | |
hs-CRP (mg/l) | 1.69 (0.66–5.31) | 0.86 (0.36–2.78) | 1.25 (0.24–3.95) | 1.58 (0.57–4.84) | 2.92 (1.03–7.43) | < 0.001* | |
Medicine | Â | Â | Â | Â | Â | Â | |
Antihypertension agents, n (%) | 2010 (86.1) | 483 (82.7) | 498 (85.3) | 509 (87.2) | 520Â (89.2) | 0.041* | |
Antidiabetics agents, n (%) | 331 (14.2) | 23 (3.9) | 48 (8.2) | 96 (16.4) | 164 (28.1) | < 0.001* | |
Lipid-lowering agents, n (%) | 251 (10.7) | 29 (5.0) | 46 (7.9) | 70 (12.0) | 106 (18.2) | < 0.001* |